Use of gabapentin to reduce chronic neuropathic pain in Fabry disease

Journal of Inherited Metabolic Disease

Volumn 26, Issue 4, 2003, Pages 413-414

  Ries, M ^a   Mengel, E ^a   Kutschke, G ^a   Kim, K S ^a   Birklein, F ^a   Krummenauer, F ^a   Beck, M ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN;

ADOLESCENT; ADULT; ANALGESIA; ARTICLE; ATAXIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; DRUG USE; FABRY DISEASE; HUMAN; MALE; MEDICAL DECISION MAKING; NEUROPATHIC PAIN; PAIN ASSESSMENT; SCORING SYSTEM; SOMNOLENCE; SPEECH DISORDER; TREATMENT OUTCOME; TREMOR; VERTIGO;

ACETIC ACIDS; ADOLESCENT; ADULT; AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; FABRY DISEASE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; NEURALGIA; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 0041418254     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025127723729     Document Type: Article

References (3)

1. Bonezzi C, Demartini L (1999) Treatment options in postherpetic neuralgia. Acta Neurol Scand Suppl 173: 25-35; discussion 48-52.
2. Schiffmann R, Kopp JB, Austin HA III, et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. J Am Med Assoc 285: 2743-2749.
3. Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 60: 1029-1052.